Short description
Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Description
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.
The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.
immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Tübingen, Baden-Wurttemberg, Germany, Europe
Founded on
January 1, 2000
Exited on
July 2, 2020
Went public on
July 2, 2020
Stock symbol
IMTX
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$56378 - 90123
Sign in for full access
Investors
Absolutely Noaccess, Cannot Access, Absolutely Noaccess, Cannot Access, Cannot Access, Noaccess, Noaccess, Absolutely Noaccess, Cannot Access, Noaccessforu, Uh Ohhhh, Uh Ohhhh, Nopepepe, Noaccess, Nopepepe, No Way, Noaccessforu, No Way, Absolutely Noaccess, Uh Ohhhh, Blurry Noaccess, Noaccess, Nopepepe, Uh Ohhhh, Noaccessforu, Noaccess, Nopepepe, Noaccess, Nopepepe, Noaccess, Noaccess, No Way, Cannot Access
Sign in for full access
Founders
Hans Rammensee, Harpreet Singh